Cardiovascular Diseases Clinical Trial
Official title:
Dietary Intervention Trial to Understand the Mechanism Underlying the 9p21 Variant Interaction With High Fruits and Vegetable Consumption
Genetic factors contribute to risk factors for cardiovascular disease, such as blood lipids, blood pressure, obesity, diabetes, and may also influence dietary choices, physical activity, and responses to stress. The most robust genetic variant associated with myocardial infarction (MI) is the 9p21 variant, which may raise the risk of MI by up to 40% in those who carry 2 copies of the gene. The investigators recently found that among those who carry the 9p21 variant, the risk of MI may be "turned off" if individuals eat a diet high in fruits and vegetables. The investigators seek to determine how a "prudent" or "anti-inflammatory" diet interacts with the 9p21 risk allele to alter the risk of MI.
Cardiovascular disease (CVD) is the leading cause of death globally. The majority of CVD is
explained by conventional risk factors including cigarette smoking, abnormal lipids, high
blood pressure, obesity, diabetes, and health behaviours including dietary intake, physical
activity, and psychosocial stressors. Genetic factors contribute to the development of these
risk factors, and directly to CVD through other novel pathways. Since the advent of high
throughput chip-based genotyping, more than 30 genetic variants have been found to be
associated with myocardial infarction. The most robust genetic variant which has been
consistently associated with myocardial infarction and other forms of arterial disease is
the 9p21 variant. This genetic variant located on Chromosome 9 is common in the population,
with 50% of people carrying one copy of the risk allele, and an additional 25% of the
population carrying two copies of the risk allele. Compared with those with no copies of the
risk allele, the risk of myocardial infarction with one copy of the risk allele is 15-20%
higher, and the increased risk among carriers of 2 risk alleles is 20-40%. To date the exact
mechanism by which the 9p21 variant increases the risk of myocardial infarction is unknown,
although some data suggests that other genes and pathways associated with cell proliferation
and inflammation are involved. Recently we made the observation that among carriers of the
9p21 variant, the risk of MI may be "turned off" if individuals consumed a diet high in
fruits and vegetables. However the "mechanism" underlying this interaction is unknown. We
seek to discover how a "Prudent" (i.e. anti-inflammatory) diet interacts with the 9p21 risk
allele(s) to alter the risk of myocardial infarction.
We postulate that a "Prudent" diet (i.e. a diet high in fruits, vegetables, whole grains,
non-processed foods) in comparison to a "Western" or "inflammatory diet" (eg, a typical
North American diet high in saturated fats and processed foods) will differentially alter
the gene expression (measured by RNA) of the 9p21 locus, change the epigenetic marks in this
region, and alter several inflammatory markers suspected to mediate the effect of 9p21 on
CVD risk (eg, hs-CRP, IF-alpha21, IFN-γ , interleukin 1-alpha, interleukin 1-beta, and
interleukin 6) among people with one or two copies of the risk allele compared to people
without the risk allele.
The proposed study offers an unique approach to studying dietary relationships with
endpoints believed to be influenced by 9p21 gene variants. Rather than testing nutritional
supplements, our results will be generalizable to the setting of most dietary counseling
practices, which aim to alter dietary patterns, not specific nutrients. This trial will help
us to unravel the basis for gene-diet interactions and gain a greater understanding of how
inflammation is linked to the development of atherosclerosis, CVD, and possibly some
cancers.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|